SUMMARY Recent studies suggest that angiotensin II is released from neuronal tissue in vitro, but the occurrence of this phenomenon in the intact brain has not yet been demonstrated. To characterize the in vivo release of immunoreactive angiotensin II, push-pull cannuias were positioned in the anterior hypothalamus in 47 Sprague-Dawley rats (200-250 g) anesthetized with Inactin (100 mg/kg i.p.). Artificial cerebrospinal fluid was perfused at 20 ^1/min, and effluent samples were collected for 15-minute periods over 2 hours. Angiotensin II was detectable (> 2.5 pg/ml) in the push-pull cannula perfusate of the majority (76%) of the rats. Spontaneous release of immunoreactive angiotensin II was constant for 2 hours in 11 rats at values averaging from 4.4 ± 1.5 to 8.2 ± 2.2 pg/ml. In addition, bilateral nephrectomy performed 48 hours before did not affect the detection of angiotensin II (n = 3). Angiotensin immunoreactivity in the rat hypothalamus was further characterized by high performance liquid chromatography. The analysis showed that the perfusate contained authentic angiotensin II as well as other angiotensin metabolites. The effect of /3-adrenergic modulation on the release of angiotensin II was assessed in 20 rats by adding isoproterenol (10~'°, 10"', and 10"' M), propranolol (10"' M), or a combination of both. Neither activation nor inhibition of hypothalamiĉ -receptors altered the spontaneous release of angiotensin II. These data demonstrate that angiotensin II and congener peptides are detectable in the microenvironment of the anterior hypothalamus of the anesthetized rat and that the release of angiotensin II immunoreactivity in the anterior hypothalamus is not modified by /3-adrenergjc receptors. 1 Substantial angiotensin converting enzyme (ACE) activity is present in hypothalamic nuclei, 2 and the proportion of messenger RNA (mRNA) coding for angiotensinogen (Aogen) in the rat hypothalamus is slightly lower than that found in mRNA extracts of rat liver.
T HE hypothalamus figures prominently in immu-
nohistochemical and biochemical studies of the brain renin-angiotensin system (RAS), as it is enriched with cell bodies and fiber tracts containing immunoreactive angiotensin II (irAng H). 1 Substantial angiotensin converting enzyme (ACE) activity is present in hypothalamic nuclei, 2 and the proportion of messenger RNA (mRNA) coding for angiotensinogen (Aogen) in the rat hypothalamus is slightly lower than that found in mRNA extracts of rat liver. 3 Immunohistochemical and biochemical studies have shown that renin is also present in the rat hypothalamus. 43 A role for the central RAS in cardiovascular regu-lation has been suggested by reports that intracerebroventricular injection of Ang II in rats increases blood pressure 6 and release of arginine vasopressin (AVP). 7 Hypothalamic injection of Ang II in conscious rats promotes drinking 8 and increases arterial pressure. 9 Ang II also promotes the release of [ 3 H]norepinephrine from anterior hypothalamus slices 10 and AVP release from the isolated hypothalamoneurohypophysial system (HNS)." Other studies suggest that Aogen release from rat brain slices is diminished markedly by inhibitors of protein synthesis. l2 Release of Ang II from rat brain neuronal cell cultures is reduced by the addition of captopril 13 and enhanced by high potassium.
14 Immunoreactive Ang II is released from the rat HNS in vitro, and this release is increased by high potassium, thereby suggesting that Ang II may act as a neuropeptide in the rat hypothalamus. 13 In the present study, we used push-pull cannula (PPC) perfusion to study the spontaneous release of Ang II and the effects of y3-receptor stimulation and /3-blockade on extracellular fluid levels of irAng II in the hypothalamus of the anesthetized rat. The latter experiments were prompted by the observation that in the rat mesenteric artery, vascular release of Ang II is modulated by y3-adrenergic receptors. 16 
Materials and Methods

Surgical Preparation and Push-Pull Cannula Perfusion
Male Sprague-Dawley rats (200-250 g) were anesthetized by intraperitoneal (i.p.) injection of Inactin (100 mg/kg), and a catheter was placed in a femoral artery for recording arterial pressure. Each rat's head was fixed in a stereotaxic headholder (Kopf Instruments, Tujunga, CA, USA), and a concentric PPC (Plastic Products, Roanoke, VA, USA) was inserted into the brain through a hole in the skull ,1.5 mm caudal to the bregma and 2.5 mm lateral to the midline. The cannula tip was lowered 8.0 mm below the dura at an angle of 14 degrees. The outer (pull) cannula was constructed of 21-gauge stainless steel tubing 11 mm in length; the inner (push) cannula was 28-gauge stainless steel tubing and protruded 0.5 mm beyond the end of the pull cannula. The area surrounding the cannula tip was perfused with an artificial cerebrospinal fluid (aCSF) 17 at an inflow rate of 20 /xl/min, and outflow rate of 21 ^il/min using a two-channel Minipuls-2 peristaltic pump (Gilson, Middleton, WI, USA). Samples were collected on ice for 15-minute intervals beginning approximately 30 minutes after the start of perfusion.
Radioactive and immunoreactive recoveries of Ang II through the PPC system were greater than 95%. To test the effect of /3-adrenergic stimulation on irAng II release, 10" l0 , 10~8, or 10" 6 M isoproterenol (Sigma Chemical, St. Louis, MO, USA) was added to the perfusate during the fourth and ninth sample-collection periods; in some trials 10" 6 M propranolol, the /3-adrenergic antagonist (Sigma Chemical), was perfused continuously and 10" 6 M isoproterenol was added during the fourth and ninth periods. In some experiments isoproterenol was perfused for two consecutive 15-minute periods. Since there were no differences in irAng II between the two periods, only the results from the first period are recorded. Prior to some experiments, rats (n = 3) were bilaterally nephrectomized under ether anesthesia. Hypothalamic PPC perfusion was done 2 days after nephrectomy as described above. When required, supplemental anesthesia (5 mg/20 fi\ i.p.) was administered between control periods; no evidence for anesthesia effects on control Ang II release was observed. At the end of each experiment, rats were killed by an overdose of Inactin and the brains were removed and fixed in formalin. Brains were sectioned and stained with cresyl violet to confirm cannula placement.
Assay of Ang II, Ang I, Proteins, and Lactate Dehydrogenase Each sample was divided into two aliquots: 200 /il was reserved for Ang II assay and the remainder was used for either protein or lactate dehydrogenase (LDH) determination. Ang II was measured by radioimmunoassay (RIA) as described previously 18 using a different antibody (CDI-4), provided by K. B. Brosnihan and R.R. Smeby. The limit of detection for this antibody was 2.5 pg/ml (0.5 pg), and comparison of eight Ang II standard curves used in this study verified that displacement of 123 I-Ang II from the antibody was significantly increased by a 5 pg/ml Ang II standard as compared with a 2.5 pg/ml standard (p<0.01). Cross-reactivity with Ang I was less than 1% and cross-reactivity with the C-terminal heptapeptide, hexapeptide, and pentapeptide fragments of Ang II was 100%. A direct RIA was performed for each 200-/xl sample. In HPLC studies (n = 2), Ang I and Ang II were measured in a pooled sample obtained from each rat. Ang I was assayed using a commercial RIA kit (New England Nuclear, Boston, MA, USA) with a minimum detection limit of 10 pg. Proteins were measured by the method of Lowry et al." and LDH was measured using the SMA II Autoanalyzer (Technicon, Tarrytown, NY, USA). The limit of detection was 8 IU/L.
Extraction and HPLC Analysis
The PPC perfusate was extracted and chromatographed as described previously. 20 The perfusate (2.5 ml) obtained from each rat was diluted with 2.5 ml of 0.13% heptafluorobutyric acid (HFBA, Sequenal grade, Pierce Chemicals, Rockford, IL, USA). The sample was applied to a Bond-Elut phenylsilica column (Analytichem, Harbor City, CA, USA) and washed with 5 ml HFBA. The angiotensin fraction was eluted with 5 ml 80% methanol/0.13% HFBA and evaporated prior to HPLC. This extract was chromatographed on an LKB 2150 HPLC (LKB Instruments, Gaithersburg, MD, USA); the solvent system consisted of 0.13% HFBA (vol/vol) in water (Buffer A) and 80% acetonitrile (Burdick and Jackson, McGaw Park, IL, USA) in 0.13% HFBA (Buffer B). To elute the extract, a linear gradient from 37% to 48% (Buffer B) over 20 minutes at a flow rate of 1.0 ml/min was used. The eluate was collected in 0.2-ml fractions that were evaporated prior to RIA. The HPLC fractions were characterized for irAng I and irANG II. Rates of recovery of irAng I and irANG II through HPLC were 72 ± 6% and 79 ± 6%, respectively. 20 Blank solvent injections were routinely performed before each sample run and indicated no carryover of irAng I and irAng II material from angiotensin standards or the perfusion extract.
Statistics
Data were evaluated by analysis of variance, followed by Dunnett's test for multiple comparisons or by paired or unpaired t test. A p value of less than 0.05 was considered significant.
Results
The time course of irAng II release during PPC perfusion of the anterior hypothalamus was studied in 45 anesthetized Sprague-Dawley rats. In 34 rats, Ang II in the PPC effluent averaged 6.9 ± 0.3 pg/ml (range, 2.5-25.5 pg/ml), whereas in 11 rats irAng II was not detected. To determine the basal level of irAng II release, PPC time control perfusion studies were done in 14 of the 45 rats. In 3 rats, irAng II was below the detection limit of this assay (< 2.5 pg/ml), whereas in the other 11, irAng II values in the perfusate ranged from 2.5 to 25.5 pg/ml. Figure 1 illustrates that the level of irAng II in the PPC perfusate of 11 rats was relatively constant, averaging from 4.4 ± 1.5 to 8.2 ± 2.2 pg/ml during 2 hours of perfusion. Control perfusion studies were also conducted to characterize irAng I and irAng II by HPLC (Figure 2 ). The HPLC profiles obtained from two different rats also are shown in Figure 2 , together with profiles for Ang standards. The middle panel indicates the perfusate contained authentic Ang I and Ang II, as well as Ang-(2-10), Ang-(2-8) and Ang-(4-8). The Ang-(2-8) peak in this run is uncharacteristically broad; the latter part of this peak may represent an immunoreactive peptide that elutes just after Ang-(2-8). In the second perfusate (bottom panel), however, irAng II was detected only in fractions corresponding to authentic Ang II. The presence of irAng II metabolites or irAng I was not detected in this run. The total irAng II in the two samples varied from 16 to 40 pg/ml of perfusate. The variation in the HPLC analysis may reflect the wide range of irAng II levels found in the direct assay of the perfusate.
To evaluate the effect of /3-adrenergic modulation on irAng II in the extracellular fluid of the anterior hypothalamus, isoproterenol (10~'°, 10~8, or 10" 6 M) was added to the PPC perfusate. In 16 rats it was added during the fourth or the ninth period of perfusion, and irAng II during /3-receptor stimulation was compared with that detected during the immediately preceding control period. In 5 of 16 rats, irAng II was not detected. The results of the other 11 experiments, summarized in Figure 3 , show that PPC perfusion of isoproterenol in concentrations up to 10~6 M had no effect on the hypothalamic extracellular fluid concentration of irAng II.
The role of beta receptors in the tonic control of hypothalamic irAng II was further evaluated by administering propranolol with isoproterenol in 12 rats. In these studies, 10" 6 M propranolol was constantly perfused during 2 hours of sample collection; 10" 6 M isoproterenol was added to the perfusate during the fourth collection period. Immunoreactive Ang II was not detected in the perfusate of three rats. In the remaining nine, spontaneous irAng II release during the first 45 minutes of sample collection averaged 8.4 ± 1.0 pg/ml. This was not significantly different from mean basal irAng II values during the first 45 minutes of sample collection in the absence of propranolol, which measured 6.2 ± 0.6 pg/ml (p>0.05). During the third period of perfusion with propranolol, irAng II measured 7.5 ± 1.6 pg/ml, and with subsequent addition of 10" 6 M isoproterenol irAng II measured 4.4 ±1.1 pg/ml (p>0.05). Mean arterial pressure and heart rate did not change in response to either agent.
To evaluate an influence of the peripheral RAS on the basal and isoproterenol-modulated release of Ang II, PPC perfusion was done in three rats 48 hours after bilateral nephrectomy. Basal irAng II release was 5.3 ± 2.0.pg7ml, and infusion of 10" 6 M isoproterenol had no effect.
Push-pull cannula perfusate was also assayed for LDH {n = 2) and proteins (n = 33) as indicators of tissue injury. The LDH in the perfusate consistently measured at or below the limits of detection, and protein values averaged 26 ± 3 /ig/ml. Histological analysis of rat brains after PPC perfusion confirmed cannula placement in the anterior hypothalamus, ventroiateral to the paraventricular nucleus. In a few experiments, the cannula track entered the third ventricle, but comparison of basal irAng II release in hypothalamic and third ventricle perfusions showed no significant differences.
Discussion
The present studies demonstrate that picograrh amounts of irAng II are added continuously to the hypothalamic extracellular fluid in a majority (76%) of anesthetized rats during PPC perfusion, lasting for the 2 hours of measurement. Analysis by HPLC indicates that authentic Ang II is a component in the PPC perfusate and also provides evidence for the presence of Ang I and other angiotensin metabolites. These studies also show that nephrectomy does not influence the hypothalamic release of irAng II. Finally, these studies demonstrate that /3-adrenergic receptors do not aflFect the release of irAng II at this site in the anesthetized rat.
Immunohistochemical and biochemical studies previously identified the hypothalamus as a site containing components of the RAS. The present PPC experiments are important because they show (for the first time, to our knowledge) the release of angiotensins into the extracellular fluid of the rat hypothalamus. The different profiles of angiotensin metabolites observed in the two rats in which immunoreactive products were characterized by HPLC are not attributable to variable recoveries through the PPC in vivo system, since we have demonstrated greater than 95% recovery of exogenously added Ang II (see Materials and Methods). Although additional experiments are required to characterize the factors that account for the large interanimal variability of angiotensin peptides present in the effluent of the PPC, it is suggested that the phenomenon reflects endogenous variation in peptide turnover and metabolism. Since the presence of Ang I, Ang II, and derived metabolic products is influenced by the activity of processing enzymes (ACE and peptidases), the rate of extracellular fluid diffusion in the region surrounding the cannula tip, and the state of neuronal release and uptake mechanisms, any of these factors may individually or collectively affect the profile of angiotensins present in the effluent.
To address the possibility that formation of Ang II in the hypothalamus is dependent upon kidney renin, PPC perfusion was also carried out in nephrectomized rats. The observation that hypothalamic irAng II release was unchanged after nephrectomy agrees with the report that the rat brain possesses mRNA for renin and Aogen 21 and supports the hypothesis that Ang II is generated in the hypothalamus by a local RAS.
We also examined how neurotransmitters may modulate the local formation and release of Ang II, since the local release of Ang II by the mesenteric artery is enhanced by isoproterenol and inhibited by propranolol.' 6 Although this observation suggests the presence of angiotensinergic nerve terminals bearing /3-adrenergic receptors in the mesenteric artery, our findings show that hypothalamic Ang II release is not modified by either activation or inhibition of /3-adrenergic receptors. Moreover, a tonic influence of /3-adrenergic receptors on basal Ang II was not observed. These studies do not eliminate the possibility that /3-adrenergic receptors may be involved in the regulation of central Ang II in other regions or strains of rats, in conscious animals, or in pathological states. Nor do they eliminate /3-adrenergic modulation of Ang I release, since in these studies only /3-receptor modulation of irAng II was assessed. In conclusion, this study showed that authentic Ang II is present in the extracellular fluid of the rat hypothalamus. The results support the hypothesis that the brain possesses a mechanism for the neuronal release of angiotensin.
